Scott Legunn, MD
Rheumatology · Burlington, VTNPI 1609193184
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,104, more than ten times the $15 reported in 2022.
Across 130 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$547
- AbbVie$420
- Johnson & Johnson$337
- Novartis$190
- UCB, Inc.$131
- Aurinia Pharma U.S., Inc.$115
- plus $639 from 21 others
What the payments were for
- Food & beverage$2,24794%
- Education$1326%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 35 | $547 |
| AbbVie | 25 | $420 |
| Johnson & Johnson(2 entities) | 14 | $337 |
| Novartis | 9 | $190 |
| UCB, Inc. | 7 | $131 |
| Aurinia Pharma U.S., Inc. | 5 | $115 |
| Medtronic | 2 | $83 |
| Pfizer | 3 | $52 |
| Radius Health, Inc. | 3 | $52 |
| Sanofi | 3 | $50 |
| Zimmer Biomet | 1 | $37 |
| Octapharma USA, Inc. | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| GSK | 2 | $33 |
| Organon | 3 | $33 |
| Mallinckrodt Hospital Products Inc. | 2 | $31 |
| Sobi, Inc | 2 | $29 |
| Soleno Therapeutics, Inc. | 1 | $23 |
| Ardelyx, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Invivyd Inc | 1 | $16 |
| United Therapeutics Corporation | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
Too few rheumatology providers in Vermontto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Actemra ActpenTocilizumab | 13 | $61,139 |
| Diclofenac Sodium | 82 | $4,691 |
| Celecoxib | 83 | $2,860 |
| Colchicine | 41 | $2,141 |
| Hydroxychloroquine Sulfate | 70 | $1,846 |
| MethotrexateMethotrexate Sodium | 67 | $1,446 |
| Duloxetine Hcl | 22 | $718 |
| Prednisone | 101 | $717 |
| Omeprazole | 66 | $694 |
| Meloxicam | 85 | $405 |
| Nabumetone | 22 | $341 |
| Ibandronate Sodium | 12 | $300 |
| Gabapentin | 22 | $297 |
| Alendronate Sodium | 21 | $297 |
| Allopurinol | 26 | $231 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Burlington
- Alana NevaresBurlington$3K
- Bonita LibmanBurlington$44
- Christine JonesBurlington$14
- Sanjeev PatilBurlington$0
- Chi Chi LauBurlington$0
- Jeanne GosselinBurlington$0
- Brendan ThomsBurlington$0
- Narandra BethinaBurlington$0
- Teresa FamaBerlin$0
- Douglas DierRutland$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.